Roberta Colucci1, Silvia Moretti2. 1. Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Ospedale Piero Palagi, Viale Michelangelo 41, 50125, Florence, Italy. roberta.colucci21@gmail.com. 2. Section of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Ospedale Piero Palagi, Viale Michelangelo 41, 50125, Florence, Italy.
Abstract
PURPOSE: The aim of the present review was to discuss recent findings on the role of beta-adrenergic system in melanoma, in order to provide information on the biological responses elicited by its activation and its potential application for melanoma treatment. METHODS: A literature search was performed, and evidences regarding the involvement of stress and beta-adrenergic system in cancer and melanoma were found and discussed. RESULTS: Our search pointed out that beta-adrenergic system is a key regulator of important biological processes involved in the onset and progression of some solid tumors. In the last decade, functional beta-adrenoceptors have been also identified on melanoma cells, as well as on their microenvironment cells. Similarly to other common cancers too, the activation of such adrenoceptors by catecholamines, usually released under stress conditions, has been found to trigger pro-tumorigenic pathways contributing to cell proliferation and motility, immune system regulation, apoptosis, epithelial-mesenchymal transition, invasion and neoangiogenesis. CONCLUSIONS: The biological evidences we found clarify and sustain the clinical evidences reporting the involvement of chronic stress in melanoma onset and progression. In such scenario, it is conceivable that a therapeutic approach targeting beta-adrenergic system could constitute a novel and promising strategy for melanoma treatment.
PURPOSE: The aim of the present review was to discuss recent findings on the role of beta-adrenergic system in melanoma, in order to provide information on the biological responses elicited by its activation and its potential application for melanoma treatment. METHODS: A literature search was performed, and evidences regarding the involvement of stress and beta-adrenergic system in cancer and melanoma were found and discussed. RESULTS: Our search pointed out that beta-adrenergic system is a key regulator of important biological processes involved in the onset and progression of some solid tumors. In the last decade, functional beta-adrenoceptors have been also identified on melanoma cells, as well as on their microenvironment cells. Similarly to other common cancers too, the activation of such adrenoceptors by catecholamines, usually released under stress conditions, has been found to trigger pro-tumorigenic pathways contributing to cell proliferation and motility, immune system regulation, apoptosis, epithelial-mesenchymal transition, invasion and neoangiogenesis. CONCLUSIONS: The biological evidences we found clarify and sustain the clinical evidences reporting the involvement of chronic stress in melanoma onset and progression. In such scenario, it is conceivable that a therapeutic approach targeting beta-adrenergic system could constitute a novel and promising strategy for melanoma treatment.
Authors: Jean-Pierre Dollé; Amir Rezvan; Fred D Allen; Philip Lazarovici; Peter I Lelkes Journal: J Pharmacol Exp Ther Date: 2005-08-25 Impact factor: 4.030
Authors: Daniel J Nolan; Alessia Ciarrocchi; Albert S Mellick; Jaspreet S Jaggi; Kathryn Bambino; Sunita Gupta; Emily Heikamp; Michael R McDevitt; David A Scheinberg; Robert Benezra; Vivek Mittal Journal: Genes Dev Date: 2007-06-15 Impact factor: 11.361
Authors: Gustavo E Ayala; Hong Dai; Michael Powell; Rile Li; Yi Ding; Thomas M Wheeler; David Shine; Dov Kadmon; Timothy Thompson; Brian J Miles; Michael M Ittmann; David Rowley Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Marisa Coelho; Cátia Soares-Silva; Daniela Brandão; Franca Marino; Marco Cosentino; Laura Ribeiro Journal: J Cancer Res Clin Oncol Date: 2016-10-05 Impact factor: 4.553
Authors: Lahiru Russell; Liliana Orellana; Anna Ugalde; Donna Milne; Meinir Krishnasamy; Richard Chambers; Patricia M Livingston Journal: Integr Cancer Ther Date: 2017-03-24 Impact factor: 3.279